SCHEMBL2480149

SCHEMBL2480149

[c]1nc2c(s1)CCCc1ccccc1-2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 3/20 0.46
DRD4 P21917 1/20 0.44
NPY5R Q15761 5/20 0.43
CYP2A6 P11509 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
MAPK1 P28482 1/20 0.40
RECQL P46063 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ADORA1 P30542 1/20 0.40
TSHR P16473 1/20 0.39
ACHE P22303 2/20 0.38
NOS3 P29474 1/20 0.38
CYP19A1 P11511 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480174 0.90 ADORA1 (0.49) BCHEMAPTKDM4ENPC1MAPK1
SCHEMBL666370 0.81 MAPK8 (0.49) BCHEMAOAMAPTKDM4ENPC1
SCHEMBL1118990 0.71 DRD4 (0.45) BCHEDRD4NPY5RCYP2A6MAOA
SCHEMBL2477067 0.70 KDM4E (0.53) NPY5RMAOAMAOBMAPTKDM4E
SCHEMBL467763 0.69 DRD4 (0.50) BCHEDRD4NPY5RCYP2A6MAOA
SCHEMBL4288204 0.69 ADORA1 (0.79) BCHEMAPTKDM4ENPC1MAPK1
SCHEMBL12177816 0.69 ADORA1 (0.53) BCHEDRD4NPY5RCYP2A6MAOA
SCHEMBL30953858 0.69 ADORA1 (0.79) BCHEMAPTKDM4ENPC1MAPK1
SCHEMBL30505637 0.69 CYP2A6 (0.68) BCHEDRD4NPY5RCYP2A6MAOA
SCHEMBL3103992 0.69 CYP2A6 (0.68) BCHEDRD4NPY5RCYP2A6MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US claimed
US-20070244130-A1 Compounds and Compositions as Ppar Modulators IRM LLC (BM) 2007-10-18 US claimed
US-20070203155-A1 Compounds And Compositions As Ppar Modulators IRM LLC (BM) 2007-08-30 US claimed
US-20070191371-A1 HETEROCYCLIC MODULATORS OF PPAR KALYPSYS, INC. (US) 2007-08-16 US claimed
US-9951051-B2 Process for producing alkynylketone derivative SHIONOGI & CO., LTD. (JP) 2018-04-24 US disclosed
US-20170197943-A1 PROCESS FOR PRODUCING ALKYNYLKETONE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2017-07-13 US disclosed
EP-3150573-A1 METHOD FOR PRODUCING ALKYNYL KETONE DERIVATIVE Shionogi & Co., Ltd. (JP) 2017-04-05 EP disclosed
EP-1854789-B1 QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2013-10-09 EP disclosed
US-8426589-B2 Process for production of quinazoline derivative SHIONOGI & CO., LTD. (JP) 2013-04-23 US disclosed
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US disclosed
US-8202879-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-06-19 US disclosed
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-17 US disclosed
US-20070191371-A1 HETEROCYCLIC MODULATORS OF PPAR KALYPSYS, INC. (US) 2007-08-16 US disclosed
EP-1749003-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-02-07 EP disclosed
US-7169931-B2 Cell differentiation, cell proliferation SHIONOGI & CO., LTD. (JP) 2007-01-30 US disclosed
WO-2005116016-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2005-12-08 WO disclosed
US-20040082626-A1 Cyclic compounds exhibiting thrombopoietin receptor agonism SHIONOGI & CO., LTD. (JP) 2004-04-29 US disclosed
EP-1361220-A1 CYCLIC COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO., LTD. (JP) 2003-11-12 EP disclosed
US-20030195231-A1 Compounds exhibiting thrombopoietin receptor agonism SHIONOGI & CO., LTD. (JP) 2003-10-16 US disclosed
EP-1253142-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO., LTD. (JP) 2002-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191371-A1 HETEROCYCLIC MODULATORS OF PPAR PPARG, PPARD, PPARA BCHE 3280/4885DRD4 3285/4885NPY5R 1318/4885
US-20070203155-A1 Compounds And Compositions As Ppar Modulators PPARG, PPARA, PPARD BCHE 3613/4885DRD4 3269/4885NPY5R 2381/4885
US-20030195231-A1 Compounds exhibiting thrombopoietin receptor agonism MPL, TEK, NPY1R BCHE 4366/4885DRD4 2552/4885NPY5R 51/4885
US-20040082626-A1 Cyclic compounds exhibiting thrombopoietin receptor agonism TEK, MPL, NPY1R BCHE 4094/4885DRD4 3244/4885NPY5R 38/4885
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY ERBB2, EGFR, ABL1 BCHE 3782/4885DRD4 1075/4885NPY5R 97/4885
US-20170197943-A1 PROCESS FOR PRODUCING ALKYNYLKETONE DERIVATIVE PDK4, PDK3, PDK2 BCHE 3948/4885DRD4 923/4885NPY5R 2804/4885
US-20070244130-A1 Compounds and Compositions as Ppar Modulators PPARG, PPARA, PPARD BCHE 3613/4885DRD4 3269/4885NPY5R 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.